Shares of Entera Bio Ltd. (NASDAQ:ENTX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the six analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $9.60.
ENTX has been the topic of several recent research reports. UBS Group set a $9.00 price objective on shares of Entera Bio in a research report on Friday, September 18th. HC Wainwright restated a “buy” rating on shares of Entera Bio in a research note on Wednesday, June 24th. Cantor Fitzgerald started coverage on shares of Entera Bio in a report on Tuesday, September 22nd. They set an “overweight” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entera Bio in a research note on Friday, July 17th. Finally, Guggenheim assumed coverage on shares of Entera Bio in a research report on Thursday, September 24th. They set a “buy” rating and a $11.00 target price on the stock.
Read Our Latest Report on ENTX
Entera Bio Price Performance
Entera Bio (NASDAQ:ENTX – Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). On average, equities analysts anticipate that Entera Bio will post -0.4 EPS for the current year.
Institutional Inflows and Outflows
An institutional investor recently raised its stake in Entera Bio stock. Seven Fleet Capital Management LP increased its stake in Entera Bio Ltd. (NASDAQ:ENTX – Free Report) by 51.9% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 205,542 shares of the company’s stock after purchasing an additional 70,224 shares during the quarter. Seven Fleet Capital Management LP owned approximately 0.42% of Entera Bio worth $228,000 at the end of the most recent reporting period. 14.11% of the stock is currently owned by institutional investors and hedge funds.
About Entera Bio
Entera Bio Ltd. is a biotechnology company developing orally administered therapies based on large-molecule drugs, including proteins and peptides that are traditionally delivered by injection. The company’s proprietary delivery technology is designed to help these molecules pass through the gastrointestinal tract and reach the bloodstream, with the goal of improving convenience and patient adherence.
Entera Bio’s lead programs have focused on bone and mineral disorders. Its pipeline has included EB613, an oral formulation of parathyroid hormone (PTH 1-34, or teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral PTH product candidate intended for hypoparathyroidism.
Recommended Stories
- Five stocks we like better than Entera Bio
- Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
- O’Reilly Automotive’s Stock Slump Hides a Stronger Business
- McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
- Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test
Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.
